with squamous cell carcinomas can experience pain, cough, bleeding, vocal cord paralysis or swallowing dysfunction, as well as masses or ulcerations in the neck, oral cavity, or oropharynx (Argiris, Karamouzis, Raben, & Ferris, 2008) . In the United Kingdom (UK), approximately, 8,500-9,000 cases of SCCHN are diagnosed annually (Jones, 2014) , and the incidence has been increasing since 1995 (Gillison, Chaturvedi, Anderson, & Fakhry, 2015) .
Tobacco use and alcohol consumption are risk factors for SCCHN (National Cancer Institute, 2013) , and an association between human papillomavirus (HPV) and SCCHN, in particular for oropharyngeal tumours, has been observed (Gillison et al., 2015; Pfister & Fury, 2014; Syrjänen, 2010) . Approximately one-half to two-thirds of patients with SCCHN initially present with locally or regionally advanced disease, and 10% of patients with SCCHN have metastatic disease at diagnosis (Gold, Lee, & Kim, 2009; Won et al., 2011) . Roughly 65% of patients with locally or regionally advanced SCCHN will relapse after primary therapy and require additional treatment (Won et al., 2011) . Median overall survival for patients with metastatic SCCHN is approximately 6-10 months (van der Linden et al., 2016; Malhotra et al., 2014; Vermorken et al., 2013; Won et al., 2011) , with 1-year survival rates ranging between 38% and 43% (Adamo et al., 2004; Raguse, Gath, Oettle, & Bier, 2006; Won et al., 2011) .
Treatment options for metastatic SCCHN are limited, and there is no consensus on a treatment pathway for metastatic disease among European and UK-specific treatment guidelines. Guidelines published more than 5 years ago from the European Society for Medical Oncology (ESMO) note that palliative chemotherapy is the recommended treatment for most patients with advanced, recurrent or metastatic SCCHN who are not candidates for surgery or radiation therapy (Grégoire et al., 2010) . In contrast with the ESMO guidelines, multidisciplinary guidelines published in 2011 for the treatment of head and neck cancer issued by ENT-UK suggest that there is little evidence supporting the use of palliative chemotherapy but that there may be an emerging role for biological targeted therapies (e.g., cetuximab) in recurrent/metastatic disease (Roland & Paleri, 2011) .
Finally, the National Institute for Health and Care Excellence (NICE) clinical guidelines describe general treatment strategies (surgery, radiotherapy, or both, with or without concomitant chemotherapy) for advanced upper aerodigestive cancers but do not recommend a specific regimen for metastatic SCCHN (NICE, 2016) .
Treatment patterns and the standard of care are evolving, as the immuno-oncologic agent nivolumab was recently approved by the European Medicines Agency (EMA) for the treatment of patients with advanced or metastatic SCCHN with disease progression on or after platinum-based chemotherapy. Nivolumab is available in the UK via the Cancer Drugs Fund for patients meeting select criteria (NICE, 2017) . Both nivolumab and pembrolizumab have been approved by the United States Food and Drug Administration for patients with advanced or metastatic SCCHN with disease progression on or after platinum-based chemotherapy, and studies are on-going in earlier lines of treatment. Data are also emerging to suggest that other immuno-oncologic therapies (e.g., ipilimumab) may be effective for SCCHN (Burtness, 2015) .
With continuing improvements in treatment for advanced cancer, patients with recurrent/metastatic SCCHN increasingly may be candidates for later lines of therapy following disease progression. However, background information against which to assess the utility of emerging therapies in routine practice-specifically, realworld data characterising treatment patterns among patients with metastatic SCCHN in the European Union and the UK-is quite limited. Current treatments for the metastatic population, the sequence of successive treatments, and the impact of performance status (PS) are uncharacterised in the literature. van der Linden et al. (2016) evaluated treatments and costs associated with metastatic SCCHN in the Netherlands, but this study was not focused on patients who had progressed beyond the second line of therapy in the metastatic setting. To our knowledge, no previous studies have evaluated treatment patterns by PS or supportive care use among patients with metastatic SCCHN. The objectives of our study were to characterise and report the real-world treatment patterns and health care resource use (HCRU), both overall and by PS, for patients with a diagnosis of metastatic SCCHN who have progressed to later lines of systemic therapy in the UK.
| ME THODS

| Study design and data source
We conducted a retrospective cohort study of patients with metastatic SCCHN (either stage IVC SCCHN at initial presentation or recurrent SCCHN with distant metastasis) who had received at least three lines of systemic therapy for metastatic disease.
Medical record data were abstracted retrospectively by oncology specialists who treat patients with metastatic SCCHN in the UK.
The participating oncology specialists abstracted patient data using a secure, web-based data collection form that was developed by the authors based on study objectives. Physicians were instructed to select medical records using a quasi-random selection approach (i.e., selecting medical records for patients whose surname began with a randomly generated letter between A and Z). Abstracted data were de-identified and anonymous to the authors. This study was submitted to RTI International's Institutional Review Board and was deemed exempt from full review. Based on local ethical review board requirements in the UK, this study was similarly exempt from a full ethics committee review by the UK's National Research Ethics Service. 
| Physician and patient selection criteria
| Study measures
Physician self-reported characteristics included patient case load (i.e., the number of patients with metastatic SCCHN treated with third-line therapy in the last 12 months), number of years in practice, medical specialty, and the geographic region in the UK where they practised.
Patient characteristics abstracted from the medical records included year of birth, sex, race/ethnicity, availability of supplemental private insurance (in addition to the national health plan), smoking status, HPV status, and presence of comorbidities or medical history at the time of diagnosis of metastatic disease. Patients' age at diagnosis of metastatic disease and age at start of third-line therapy for metastatic disease were calculated from patients' year of birth.
Stage of disease at initial diagnosis and primary site of SCCHN were collected. For patients with initial diagnoses of stage I through stage IVB disease, the types of cancer-directed treatments and supportive care services patients received before diagnosis of metastatic disease were collected and analysed. Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Scale PS at metastatic SCCHN diagnosis but prior to the first line of systemic therapy ("at metastatic diagnosis"), as well as at start of each subsequent therapy line, was documented. Karnofsky Performance Scale PS scores were converted to ECOG scores to facilitate comparison of PS across all patients (ESMO, 2008; Oken et al., 1982) .
Systemic therapy treatment patterns from the time of metastatic SCCHN diagnosis until the time of last medical record or death were evaluated. Treatment guidelines and published literature informed which treatments were listed on the data collection form (Grégoire et al., 2010; National Comprehensive Cancer Network, 2013) , although physicians were able to enter other treatments that were not listed. Survival data were analysed using Kaplan-Meier methods to estimate survival from initiation of third-line systemic therapy for metastatic SCCHN, as well as from the time of metastatic diagnosis. For patients who were still alive or had unknown survival status, observation was censored at the date of the last entry in their medical record.
The number and percentage of patients receiving specific supportive care services after metastatic diagnosis and prior to discontinuation of last systemic therapy, as well as after discontinuation of last systemic therapy until death or last medical record were documented. Supportive care services were also documented before metastatic diagnosis among the subset of patients initially presenting with stage I-IVB disease. Information on metastatic SCCHN-related HCRU (i.e., outpatient visits and hospitalisations) was collected and reported separately for the periods during systemic therapy and after the end of last systemic therapy. In addition to the number of SCCHN-related outpatient visits and hospitalisations, length of stay for hospitalisation, and time on wards (e.g., general ward, oncology, intensive care unit) were collected. Hospitalisations with discharge dates occurring on the same day as admission dates were assumed to have a 1-day length of stay (i.e., hospitalisation length of stay was calculated per visit by subtracting the admission date index from the discharge date index and adding 1).
| Statistical analyses
All study measures were summarised descriptively through the tabular display of values characterising mean and standard deviations (SDs) for continuous variables of interest and frequency distributions for categorical variables. Time-related outcomes (e.g., survival)
were estimated using the Kaplan-Meier method.
Exploratory multivariable logistic regression analyses were conducted to formally assess the risk of covariate-adjusted HCRU outcomes of interest (i.e., whether patients had any SCCHN-related hospitalisations, emergency department visits, office visits/consults, outpatient visits in hospital clinics, and outpatient palliative care visits). Covariates that were expected to be associated with the HCRU outcomes of interest were included in the models (e.g., age at metastatic diagnosis, sex, PS at metastatic diagnosis, comorbidity burden). Odds ratios from the logistic regression models are reported.
All analyses were conducted using SAS statistical software, versions 9.3 and 9.4 (Cary, NC: SAS Institute, Inc.; 2011, 2013).
| RE SULTS
| Physician characteristics
A total of 40 physicians were recruited from across the UK for study participation. Participating physicians were specialists in the fields of clinical oncology (52.5%) and medical oncology (47.5%). Mean 
| Patient characteristics
A total of 220 patients from the UK were included in the study (Table 1) Among patients with initial diagnoses of stage I through stage IVB disease, 83.8% received any radiotherapy, 64.8% received any surgery, and 60.0% received any systemic chemotherapy prior to diagnosis with metastatic disease (Table 1) . Most patients received a combination of these cancer-directed treatments (Supporting Information Table S1 ). Only 4.8% of patients received radiotherapy alone, 13.3% of patients received surgery alone; there were no patients who received systemic chemotherapy alone.
Most patients (71.8%) were reported to have at least one comorbidity at the time of metastatic SCCHN diagnosis; 23.6% of patients were reported to have no comorbidity; and 4.5% of patients had an unknown comorbidity status. Comorbidities reported in more than 10% of the population included hypertension (42.7%), chronic obstructive pulmonary disease or asthma (26.4%), alcohol abuse or alcoholism (10.9%), diabetes with end organ involvement (10.5%), and diabetes without end organ involvement (10.5%). Only two patients were reported to be HPV positive.
At metastatic diagnosis, 15.9% of patients had an ECOG PS score of 0, 78.6% had an ECOG PS score of 1, and 4.1% had an ECOG PS score ≥ 2 (Figure 1 ). There was a downward trend in PS as patients progressed to later lines of therapy.
| Treatment patterns
| Anticancer treatment use
Of the 220 study participants (all of whom received at least three lines of systemic therapy for metastatic SCCHN), only 4 patients agents. Among all 36 distinct drug regimens, the most commonly reported were single-agent docetaxel (21.1%), cisplatin + 5-fluorouracil (5-FU) (16.4%), and single-agent cetuximab (9.3%).
The most frequently used regimens varied by line of therapy and by PS measured at the start of each line of therapy (Table 3, with additional details on all systemic treatments used in each line of therapy presented in Supporting Information Table S2 ). In the first line, cisplatin + 5-FU was the most commonly reported regimen (46.4%) overall, followed by cetuximab + cisplatin + 5-FU (16.4%), and carboplatin + 5-FU (11.8%). Cisplatin + 5-FU was the most common first-line treatment among patients with PS 0 or 1, and carboplatin + 5-FU was the most common first-line treatment among patients with PS ≥ 2. In the second line, the most common regimens overall were single-agent docetaxel (45.0%) and singleagent paclitaxel (12.7%), with single-agent cetuximab (8.6%) and carboplatin + paclitaxel (8.6%) tied for the third most commonly reported regimen. Docetaxel was the most common second-line treatment among patients with PS 0 or 1, and cetuximab was the most common second-line treatment among patients with PS ≥ 2. In the third line, single-agent cetuximab (19.6%) and single-agent methotrexate (19.6%) were the most commonly reported regimens overall, followed by single-agent docetaxel (18.2%). Docetaxel was the most common third-line treatment among patients with PS 0 or 1, and methotrexate was the most common third-line treatment among patients with PS ≥ 2. Overall, the mean number of cycles varied across regimens and lines of therapy, ranging from 4.1 cycles for third-line docetaxel to 6.6 cycles for third-line cetuximab. Among the four patients overall who received fourth-line therapy, no patient received the same fourth-line therapy (Supporting Information Table S2 ).
Overall, the most frequently used regimen sequence was cisplatin + 5-FU as first-line therapy, single-agent docetaxel as second-line therapy, and single-agent cetuximab as third-line therapy. This sequence of regimens was received by 8.6% of patients (n = 19).
| Supportive care use
Among the 105 patients initially diagnosed with stage I-IVB SCCHN, 91.4% received some amount of supportive care prior to diagnosis of metastatic disease ( 
| Health care resource use
During systemic therapy, the HCRU categories most commonly reported for patients were outpatient office visits (70.0% with any visit) and palliative care visits (44.6% with any visit) ( Table 5 ). Among patients with any visit in either setting, a mean (SD) of 24.8 (13.7) outpatient office visits and 3.8 (3.0) palliative care visits were reported. Fewer patients had outpatient visits in a hospital clinic or cancer centre, emergency department visits on an outpatient basis, or hospitalisations (overnight or day admissions, excluding emergency department visits).
Among all 220 patients, 38.6% of patients had no hospitalisations, 11.4% had one hospitalisation, 6.8% had two hospitalisations, 8.6% had more than two hospitalisations, and 34.6% had an unknown number of stays. Among the 59 patients with any hospitalisations during this period, a mean (SD) of 2.9 (2.8) visits was reported overall. Among the 171 hospitalisations that were reported, admissions were primarily to oncology wards (83.6%) and general wards (14.0%). Among the 90 hospitalisations with known admission and discharge dates, the mean (SD) length of stay was 5.2 (3.4) days.
Among the 164 patients who discontinued last systemic therapy during the study, HCRU declined after the end of last systemic therapy across all categories of care, with two exceptions (outpatient hospital clinic or cancer centre visits; hospice, long-term care, or other end-of-life care services) ( Table 5 ). The percentage of patients with at least one office visit decreased during this period (from 70.0% to 50.6%), as did the percentage of patients with at least one palliative care visit (from 44.6% to 36.0%). The proportion of patients with at least one emergency department visit on an outpatient basis or at least one hospitalisation also decreased during this period (from 20.5% to 14.0% and from 26.8% to 8.5%, respectively).
In addition, among patients with any visit across settings, the mean number of visits declined after the end of last systemic therapy, with the exception of hospice, long-term care, or other end-of-life care services. After the end of last systemic therapy, 48.2% of patients had no hospitalisations, 7.9% had one hospitalisation, 0.6% had two hospitalisations, and 43.3% had an unknown number of stays; no patients had more than two hospitalisations during this period. Among the 15 hospitalisations that were reported, admissions were primarily to oncology wards (66.7%) and general wards (26.7%). Among the 10 hospitalisations with known admission and discharge dates, the mean (SD) length of stay was 6.9 (3.5) days. Table 6 of surgery or systemic therapy for non-metastatic disease and the receipt of radiotherapy for metastatic disease were associated with select categories of HCRU.
| Survival
The estimated median survival from start of third-line treatment was 
| D ISCUSS I ON
Limited data are available for countries outside of the United States that describe treatment patterns in advanced SCCHN, characterise information by PS and provide information on supportive care use.
To our knowledge, only one previous study has explored utilisation TA B L E 3 Patients receiving the most commonly used systemic treatments in each line of therapy, overall and by ECOG PS PS was requested before each line of therapy but was not reported for all patients; therefore, the total number of patients by PS in each line of therapy is <220, and the sum varies among lines of therapy. For each line of therapy, the three most commonly used treatments, overall and by ECOG PS, are presented in bold. Where two or three regimens were reported with equal frequency within a stratum (line of therapy and PS), more than three treatments are presented in bold for that stratum. Patients' age >50 years and smoking have both been identified as risk factors for head and neck cancer in the UK (Macmillan Cancer Support, 2012) . This study included a total of 220 patients, with a median age of 60 years; more than 90% of the study population was
Caucasian, and 85% were either current or former smokers. While a significant amount of research has emphasised the relevance of HPV as a prognostic risk factor in this population, as well as the recommendation to include it as part of a patient's risk assessment (Gillison et al., 2000; Grégoire et al., 2010; Pfister & Fury, 2014; Syrjänen, 2010) , data on HPV status were not reported for the majority of this cohort.
Approximately, half of patients (51.8%) in the present study had initial diagnoses of stage IVC disease, which is much higher than what has been previously reported (~10%) (Gold et al., 2009) . The majority of patients had relatively good PS at diagnosis and prior to receipt of first-line therapy. Overall, there was substantial heterogeneity in the types of systemic therapy received by patients, both overall and by PS. A total of 36 distinct chemotherapy regimens were reported across all lines of therapy, which was likely a function of the few effective therapeutic options available for these patients at the time of this study. For most patients with local, regional, and metastatic recurrences of SCCHN, the ESMO guidelines recommend palliative chemotherapy as the standard treatment, with a first-line option of cetuximab plus a platinum agent and 5-FU noted for "fit patients" (Grégoire et al., 2010 ). In the current study, 17.7% of patients re- or 1, the most common first-line treatment was cisplatin + 5-FU; for patients with PS ≥ 2, the most common first-line treatment was carboplatin + 5-FU. Cisplatin tends to be more poorly tolerated as compared with carboplatin, which likely explains its less-frequent use for patients with poorer PS. Docetaxel was the most common secondand third-line treatments for patients with a PS score of 0 or 1 (vs.
cetuximab and methotrexate, respectively, for patients with PS ≥ 2).
Among the 105 patients with initial diagnoses of stage I through stage IVB disease, most received surgery, radiotherapy, or systemic therapy, alone or in combination, prior to diagnosis with metastatic disease. These findings were consistent with ESMO guidelines, which note that specific combinations of these treatment options for early stage (I-II) and locally advanced stage (III-IV) disease depend on the primary tumour location and extension, as well as expected patient outcomes and prognoses (Grégoire et al., 2010) . In addition, the stringent selection of patients also likely influenced the findings related to patient characteristics, including PS, treatment patterns, and HCRU. In particular, patients with PS ≥ 2 (n = 9) at the first diagnosis of metastatic disease received three lines of therapy; these patients were likely "more fit" and/or perhaps had better outcomes from treatments received than what is typical for the general population of patients with newly diagnosed metastatic SCCHN with poor PS. It is also important to take into account the subjectivity of a clinician's assessment when assigning a PS rating; some patients may have been mischaracterised as having PS ≥ 2 when they perhaps had a PS of 1.
Furthermore, because the goal of the study was to evaluate treatment patterns and outcomes among patients treated in routine clinical practice, the results are limited to those treatments that were available at the time of the study. Specifically, patients participating in any interventional clinical trial, including those of PD-1 inhibitors, at the time of our study (January 2011 -August 2014 were not included. Patients selected for study inclusion represent a convenience sample, in that the records were obtained from physicians who were willing to participate in the study. Our findings may therefore not be generalisable to the overall metastatic SCCHN population in the UK and must be considered within the context of an evolving treatment landscape, given the recent availability of nivolumab, as well as the potential future availability of other treatments that are under clinical investigation in this setting.
The importance of HPV status and prognosis in SCCHN is appreciated, and although treatment guidelines recommend testing for HPV DNA in oropharyngeal tumours (Grégoire et al., 2010; NICE, 2016; Roland & Paleri, 2011) , limited data were reported regarding HPV status for this population in this study. The data collected in this study were potentially subject to data-entry errors as they were directly entered by physicians; the authors did not review patients' medical record data to confirm the accuracy of information collected. Moreover, physicians reported data based on patients' medical records to which they had access. HCRU information pertinent to the patient's SCCHN condition and study objectives but not captured in the patient's chart to which the participating physician had access was not included in our analysis and may be underreported. Data on hospitalisations in patients' charts also lacked dates of service for a substantial proportion of the study's sample, leading to less robust estimates of hospitalisation length of stay data. Finally, the data collection form was designed to prioritise collection of key information in support of study objectives while balancing physician time burden. There may be additional measures or analyses that would be useful in understanding variations in treatment and outcomes. For example, differential patient follow-up time was not accounted for in the exploratory regression analyses and more advanced models that account for differential follow-up (e.g.,
Cox proportional hazards models) were not feasible with the data collected (i.e., lack of dates of service for many HCRU categories).
| CON CLUS ION
This study provides useful information on patient characteristics, treatment patterns, HCRU, and survival in a real-world population of patients with metastatic SCCHN who received at least three lines of systemic therapy in the UK in the pre-immunotherapy era. Patterns of care and HCRU varied among patients with metastatic SCCHN, and specific systemic therapies varied by patient PS. Given the lack of existing data on this particular patient population and on-going development efforts to identify new treatments for metastatic SCCHN, findings from the current study help to fill critical gaps in the literature. With the EMA approval of nivolumab for advanced SCCHN, as well as several other studies of immunotherapy on-going, future real-world research should explore how treatment patterns have evolved and the extent to which these treatments provide meaningful improvement in outcomes relative to the pre-immunotherapy era. 
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